Cromos Pharma insights on master protocols

27 April 2020
We are delighted to share with you the just published article that provides an overview of master protocols written by Cromos Pharma’s CEO, Dr Vlad Bogin.

Master protocols are disrupting the clinical trial space by offering a more comprehensive and adaptive approach to studying treatments for the most complex of diseases.

This paper was submitted before COVID-19 became the reality and thus it doesn’t mention the recently initiated Solidarity trial, a platform design trial launched by WHO to evaluate potential treatments for SARS-CoV-2, or the UK’s RECOVERY trial, using an adaptive design approach, led by Cambridge University with the NHS.


Read the full article here: Master protocols: New directions in drug discovery.

You can also view our recent Insights@CromosPharma presentation on Master Protocols here.

We hope that you enjoy this article and would be happy to answer any questions about master protocols or any other trial-related queries that you might have. Please email bd@cromospharma.com for all queries and our team will direct your question to our relevant specialist.
Back to the news